AQST - רווח נקי למניה (EPS TTM) Aquestive Therapeutics Inc

Aquestive Therapeutics (AQST) relies on external partners for the production and distribution of medications. The annual net income per share trend confirms the current momentum, where the value of -0.64 reflects this status. Aquestive Therapeutics is scaling its business via the PharmFilm platform, converting tablets into films. Mid-term growth is driven by expectations of FDA approval for an anaphylaxis drug for market launch.
פילוחי נתונים אנליטיים מרוכזים עבור Aquestive Corp (AQST)

This indicator measures the net income per share over a rolling year, allowing for an assessment of real return on equity by stripping out one-time volatility. By analyzing the net income per share over the last four quarters, an investor will see Aquestive Therapeutics (AQST) transitioning to profitability following the approval of a key drug and the execution of distribution agreements, which will serve as a signal for a valuation rerating of the asset.